Prof Kim Mulholland
Prof Kim Mulholland
Details
Role
Group Leader / Snr Princ Research Fellow
Research area
Infection and Immunity
Group
New Vaccines
Contact
Available for student supervision
Kim Mulholland is an Australian paediatrician, trained at Melbourne University and the Royal Children's Hospital, Melbourne. He completed post-graduate training in immunology, respiratory medicine and tropical medicine.
Kim’s main research focus is vaccines, and he is considered an authority in his field. He has been a member of the WHO SAGE (Scientific Advisory Group of Experts) on immunization since 2020.
Kim has been a Senior Principal Research Fellow at MCRI since 2003 and leads the New Vaccines Research Group. He established leading pneumococcal microbiology and immunology laboratories at the Murdoch Children's Research Institute (MCRI), Melbourne, along with major field research programs in Vietnam, Fiji, Indonesia and Mongolia. He is Co-Director of Global Health at MCRI.
A major area of work currently is 3 Covid Vaccine clinical trials being conducted in Australia, Indonesia and Mongolia.
Kim has been leading a programme of PCV clinical trials in Vietnam for the past decade. He also leads HPV research programs in Mongolia, Vietnam and Ethiopia. He has worked on RSV research projects for over 30 years and currently leads projects in Mongolia and Vietnam. He has co-led the typhoid research project in Fiji since 2012. He has been involved in the oversight of many vaccine trials, serving on steering committees or DSMBs for a range of vaccines including Pneumococcal, Dengue, RSV, malaria and Covid-19 vaccines.
Kim joined the Medical Research Council Laboratories, Gambia in 1989, where he developed a program of research covering all aspects of the problem of childhood pneumonia. This included studies of the aetiology, clinical signs, and treatment of pneumonia cases, with particular reference to very young infants and malnourished children.
These studies helped to guide WHO policy in the field and contributed to the development of the strategy of Integrated Management of Childhood Illness (IMCI), as well as guiding oxygen and antibiotic management for hospitalized children. In the Gambia he also worked on several projects relating indoor air pollution to pneumonia. His Hib vaccine trials were the first to demonstrate the capacity of conjugate vaccines to prevent bacterial pneumonia and paved the way for Hib vaccine introduction in Africa.
After six years in the Gambia, he joined WHO HQ where he oversaw the development of standardized methods for the evaluation of pneumonia vaccines in developing countries. At WHO he was also the focal point for air pollution in the Child and Adolescent Health Department and helped design the RESPIRE study.
Since leaving WHO in 2000 he has continued to work in the pneumonia field with particular emphasis on vaccines. He was one of the founders of the Global Action Plan for Pneumonia, and one of the leaders of the successful Hib Initiative project that saw the introduction of Hib vaccines into the poorest countries of the world.
Feel free to mention Kim in a post or ask him about Vaccine, Pneumococcal, HPV, and Typhoid.
Kim’s main research focus is vaccines, and he is considered an authority in his field. He has been a member of the WHO SAGE (Scientific Advisory Group of Experts) on immunization since 2020.
Kim has been a Senior Principal Research Fellow at MCRI since 2003 and leads the New Vaccines Research Group. He established leading pneumococcal microbiology and immunology laboratories at the Murdoch Children's Research Institute (MCRI), Melbourne, along with major field research programs in Vietnam, Fiji, Indonesia and Mongolia. He is Co-Director of Global Health at MCRI.
A major area of work currently is 3 Covid Vaccine clinical trials being conducted in Australia, Indonesia and Mongolia.
Kim has been leading a programme of PCV clinical trials in Vietnam for the past decade. He also leads HPV research programs in Mongolia, Vietnam and Ethiopia. He has worked on RSV research projects for over 30 years and currently leads projects in Mongolia and Vietnam. He has co-led the typhoid research project in Fiji since 2012. He has been involved in the oversight of many vaccine trials, serving on steering committees or DSMBs for a range of vaccines including Pneumococcal, Dengue, RSV, malaria and Covid-19 vaccines.
Kim joined the Medical Research Council Laboratories, Gambia in 1989, where he developed a program of research covering all aspects of the problem of childhood pneumonia. This included studies of the aetiology, clinical signs, and treatment of pneumonia cases, with particular reference to very young infants and malnourished children.
These studies helped to guide WHO policy in the field and contributed to the development of the strategy of Integrated Management of Childhood Illness (IMCI), as well as guiding oxygen and antibiotic management for hospitalized children. In the Gambia he also worked on several projects relating indoor air pollution to pneumonia. His Hib vaccine trials were the first to demonstrate the capacity of conjugate vaccines to prevent bacterial pneumonia and paved the way for Hib vaccine introduction in Africa.
After six years in the Gambia, he joined WHO HQ where he oversaw the development of standardized methods for the evaluation of pneumonia vaccines in developing countries. At WHO he was also the focal point for air pollution in the Child and Adolescent Health Department and helped design the RESPIRE study.
Since leaving WHO in 2000 he has continued to work in the pneumonia field with particular emphasis on vaccines. He was one of the founders of the Global Action Plan for Pneumonia, and one of the leaders of the successful Hib Initiative project that saw the introduction of Hib vaccines into the poorest countries of the world.
Feel free to mention Kim in a post or ask him about Vaccine, Pneumococcal, HPV, and Typhoid.
Kim Mulholland is an Australian paediatrician, trained at Melbourne University and the Royal Children's Hospital, Melbourne. He completed post-graduate training in immunology, respiratory medicine and tropical medicine.
Kim’s main research focus...
Kim’s main research focus...
Kim Mulholland is an Australian paediatrician, trained at Melbourne University and the Royal Children's Hospital, Melbourne. He completed post-graduate training in immunology, respiratory medicine and tropical medicine.
Kim’s main research focus is vaccines, and he is considered an authority in his field. He has been a member of the WHO SAGE (Scientific Advisory Group of Experts) on immunization since 2020.
Kim has been a Senior Principal Research Fellow at MCRI since 2003 and leads the New Vaccines Research Group. He established leading pneumococcal microbiology and immunology laboratories at the Murdoch Children's Research Institute (MCRI), Melbourne, along with major field research programs in Vietnam, Fiji, Indonesia and Mongolia. He is Co-Director of Global Health at MCRI.
A major area of work currently is 3 Covid Vaccine clinical trials being conducted in Australia, Indonesia and Mongolia.
Kim has been leading a programme of PCV clinical trials in Vietnam for the past decade. He also leads HPV research programs in Mongolia, Vietnam and Ethiopia. He has worked on RSV research projects for over 30 years and currently leads projects in Mongolia and Vietnam. He has co-led the typhoid research project in Fiji since 2012. He has been involved in the oversight of many vaccine trials, serving on steering committees or DSMBs for a range of vaccines including Pneumococcal, Dengue, RSV, malaria and Covid-19 vaccines.
Kim joined the Medical Research Council Laboratories, Gambia in 1989, where he developed a program of research covering all aspects of the problem of childhood pneumonia. This included studies of the aetiology, clinical signs, and treatment of pneumonia cases, with particular reference to very young infants and malnourished children.
These studies helped to guide WHO policy in the field and contributed to the development of the strategy of Integrated Management of Childhood Illness (IMCI), as well as guiding oxygen and antibiotic management for hospitalized children. In the Gambia he also worked on several projects relating indoor air pollution to pneumonia. His Hib vaccine trials were the first to demonstrate the capacity of conjugate vaccines to prevent bacterial pneumonia and paved the way for Hib vaccine introduction in Africa.
After six years in the Gambia, he joined WHO HQ where he oversaw the development of standardized methods for the evaluation of pneumonia vaccines in developing countries. At WHO he was also the focal point for air pollution in the Child and Adolescent Health Department and helped design the RESPIRE study.
Since leaving WHO in 2000 he has continued to work in the pneumonia field with particular emphasis on vaccines. He was one of the founders of the Global Action Plan for Pneumonia, and one of the leaders of the successful Hib Initiative project that saw the introduction of Hib vaccines into the poorest countries of the world.
Feel free to mention Kim in a post or ask him about Vaccine, Pneumococcal, HPV, and Typhoid.
Kim’s main research focus is vaccines, and he is considered an authority in his field. He has been a member of the WHO SAGE (Scientific Advisory Group of Experts) on immunization since 2020.
Kim has been a Senior Principal Research Fellow at MCRI since 2003 and leads the New Vaccines Research Group. He established leading pneumococcal microbiology and immunology laboratories at the Murdoch Children's Research Institute (MCRI), Melbourne, along with major field research programs in Vietnam, Fiji, Indonesia and Mongolia. He is Co-Director of Global Health at MCRI.
A major area of work currently is 3 Covid Vaccine clinical trials being conducted in Australia, Indonesia and Mongolia.
Kim has been leading a programme of PCV clinical trials in Vietnam for the past decade. He also leads HPV research programs in Mongolia, Vietnam and Ethiopia. He has worked on RSV research projects for over 30 years and currently leads projects in Mongolia and Vietnam. He has co-led the typhoid research project in Fiji since 2012. He has been involved in the oversight of many vaccine trials, serving on steering committees or DSMBs for a range of vaccines including Pneumococcal, Dengue, RSV, malaria and Covid-19 vaccines.
Kim joined the Medical Research Council Laboratories, Gambia in 1989, where he developed a program of research covering all aspects of the problem of childhood pneumonia. This included studies of the aetiology, clinical signs, and treatment of pneumonia cases, with particular reference to very young infants and malnourished children.
These studies helped to guide WHO policy in the field and contributed to the development of the strategy of Integrated Management of Childhood Illness (IMCI), as well as guiding oxygen and antibiotic management for hospitalized children. In the Gambia he also worked on several projects relating indoor air pollution to pneumonia. His Hib vaccine trials were the first to demonstrate the capacity of conjugate vaccines to prevent bacterial pneumonia and paved the way for Hib vaccine introduction in Africa.
After six years in the Gambia, he joined WHO HQ where he oversaw the development of standardized methods for the evaluation of pneumonia vaccines in developing countries. At WHO he was also the focal point for air pollution in the Child and Adolescent Health Department and helped design the RESPIRE study.
Since leaving WHO in 2000 he has continued to work in the pneumonia field with particular emphasis on vaccines. He was one of the founders of the Global Action Plan for Pneumonia, and one of the leaders of the successful Hib Initiative project that saw the introduction of Hib vaccines into the poorest countries of the world.
Feel free to mention Kim in a post or ask him about Vaccine, Pneumococcal, HPV, and Typhoid.
Top Publications
- David, SC, Brazel, EB, Singleton, EV, Minhas, V, Laan, Z, Scougall, C, Chen, AY, Wang, H, Gates, CJ, McLean, KT, et al. A Nonadjuvanted Whole-Inactivated Pneumococcal Vaccine Induces Multiserotype Opsonophagocytic Responses Mediated by Noncapsule-Specific Antibodies. mBio e02367 -e02322 2022 view publication
- Fagerli, K, Ulziibayar, M, Suuri, B, Luvsantseren, D, Narangerel, D, Puversuren, B, Tholmon, B, Gessner, BD, Dunne, EM, Grobler, AC, et al. Epidemiology of pneumonia in hospitalized adults ≥18 years old in four districts of Ulaanbaatar, Mongolia, 2015–2019. The Lancet Regional Health - Western Pacific 100591 2022 view publication
- Wilkes, C, Graham, H, Walker, P, Duke, T, Duke, T, Graham, H, Graham, S, Gray, A, Gwee, A, von Mollendorf, C, et al. Which children with chest-indrawing pneumonia can be safely treated at home, and under what conditions is it safe to do so? A systematic review of evidence from low- and middle-income countries. Journal of Global Health 12: 10008 2022 view publication
- van Zandvoort, K, Bobe, MO, Hassan, AI, Abdi, MI, Ahmed, MS, Soleman, SM, Warsame, MY, Wais, MA, Diggle, E, McGowan, CR, et al. Social contacts and other risk factors for respiratory infections among internally displaced people in Somaliland. Epidemics 41: 100625 2022 view publication
- Hume-Nixon, M, Lim, R, Russell, F, Graham, H, von Mollendorf, C, Mulholland, K, Gwee, A, Duke, T, Graham, H, Graham, S, et al. Systematic review of the clinical outcomes of pneumonia with a penicillin-group resistant pneumococcus in respiratory and blood culture specimens in children in low- and middle-income countries. Journal of Global Health 12: 10004 2022 view publication
Page 1 of 78
Professional activities
Share //
